Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Brachytherapy proves beneficial regardless of treatment duration

Key clinical point: Brachytherapy improves survival in patients with locally advanced cervical cancer regardless of treatment duration.

Major finding: The median overall survival was 113.7 months in patients who received brachytherapy within 8 weeks, 75.7 months (95% CI, 69.7-82.4) in those who received brachytherapy for more than 8 weeks, 58.5 months (95% CI, 48.3-74.2) in patients who received only chemoradiation within 8 weeks, and 46.2 months (95% CI, 39.8-56.4) in those who received only chemoradiation for more than 8 weeks.

Study details: A retrospective study of 18,592 patients.

Disclosures: The speaker had no relevant financial disclosures.

Citation:

Korenaga TRK et al. SGO 2019. Abstract 10.